trending Market Intelligence /marketintelligence/en/news-insights/trending/G7B0Rs7iN-D1QOmY8ifyTQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ImmunoCellular reports phase 1 trial results for brain cancer drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ImmunoCellular reports phase 1 trial results for brain cancer drug

ImmunoCellular Therapeutics Ltd. reported results from the phase 1 trial of its brain cancer drug candidate ICT-121 at the American Society of Clinical Oncology's annual meeting.

The trial enrolled 20 patients suffering from glioblastoma, a cancer that forms from star-shaped cells in the brain called astrocytes. It is defined by high incidence of tumor recurrence, thought to be triggered by tumor cells resistant to irradiation and chemotherapy.

ICT-121 is a dendritic cell-based immunotherapy that targets the cancer stem cell marker CD133 which is overexpressed in solid tumors, including glioblastoma, non-small cell lung, colon, ovarian, pancreatic and breast cancers.

The trial had safety and tolerability as primary endpoints and overall survival and progression-free survival as secondary endpoints.

The trial results showed that six of 20 patients were still alive as of April with survival ranging from 10 to 24 months. The results also showed that ICT-121 was generally safe and well tolerated. Immune response data from the trial was still unavailable and will provide insight into the effectiveness of the drug in inducing the formation of cytotoxic T cells targeting CD133.

The Los Angeles-based clinical-stage company said that the preliminary findings from the trial were encouraging, especially considering the lack of therapeutic options for patients with this disease, and the drug warranted further investigation.